Logo image of ATRS

ANTARES PHARMA INC (ATRS) Stock Fundamental Analysis

NASDAQ:ATRS - Nasdaq - US0366421065 - Common Stock

5.59  0 (0%)

After market: 5.59 0 (0%)

Fundamental Rating

3

Overall ATRS gets a fundamental rating of 3 out of 10. We evaluated ATRS against 195 industry peers in the Pharmaceuticals industry. The financial health of ATRS is average, but there are quite some concerns on its profitability. ATRS shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATRS had positive earnings in the past year.
ATRS Yearly Net Income VS EBIT VS OCF VS FCFATRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M

1.2 Ratios

Industry RankSector Rank
ROA 17.97%
ROE 26.33%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATRS Yearly ROA, ROE, ROICATRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40

1.3 Margins

Industry RankSector Rank
OM 14.87%
PM (TTM) 25.15%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATRS Yearly Profit, Operating, Gross MarginsATRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40 60

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ATRS has more shares outstanding
Compared to 1 year ago, ATRS has an improved debt to assets ratio.
ATRS Yearly Shares OutstandingATRS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M
ATRS Yearly Total Debt VS Total AssetsATRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 8.15 indicates that ATRS is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 0.10 indicates that ATRS is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 8.15
ROIC/WACCN/A
WACCN/A
ATRS Yearly LT Debt VS Equity VS FCFATRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M 100M 150M

2.3 Liquidity

ATRS has a Current Ratio of 2.96. This indicates that ATRS is financially healthy and has no problem in meeting its short term obligations.
ATRS has a Quick Ratio of 2.76. This indicates that ATRS is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.76
ATRS Yearly Current Assets VS Current LiabilitesATRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

ATRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 350.00%, which is quite impressive.
Looking at the last year, ATRS shows a very strong growth in Revenue. The Revenue has grown by 22.99%.
The Revenue has been growing by 28.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)350%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%533.33%
Revenue 1Y (TTM)22.99%
Revenue growth 3Y42.49%
Revenue growth 5Y28.65%
Sales Q2Q%10.42%

3.2 Future

ATRS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.76% yearly.
The Revenue is expected to grow by 17.75% on average over the next years. This is quite good.
EPS Next Y-69.78%
EPS Next 2Y-9.18%
EPS Next 3Y8.49%
EPS Next 5Y41.76%
Revenue Next Year15.42%
Revenue Next 2Y18.38%
Revenue Next 3Y17.73%
Revenue Next 5Y17.75%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ATRS Yearly Revenue VS EstimatesATRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M
ATRS Yearly EPS VS EstimatesATRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 1 1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 20.70, which indicates a rather expensive current valuation of ATRS.
Compared to an average S&P500 Price/Earnings ratio of 26.65, ATRS is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 68.50, the valuation of ATRS can be described as expensive.
The average S&P500 Price/Forward Earnings ratio is at 21.27. ATRS is valued rather expensively when compared to this.
Industry RankSector Rank
PE 20.7
Fwd PE 68.5
ATRS Price Earnings VS Forward Price EarningsATRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 29.05
ATRS Per share dataATRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.18%
EPS Next 3Y8.49%

More info and screens

0

5. Dividend

5.1 Amount

ATRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANTARES PHARMA INC

NASDAQ:ATRS (5/23/2022, 8:12:09 PM)

After market: 5.59 0 (0%)

5.59

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-10 2022-05-10/amc
Earnings (Next)08-03 2022-08-03
Inst Owners0.26%
Inst Owner Change0%
Ins Owners6.83%
Ins Owner Change0%
Market Cap955.06M
Analysts73.33
Price Target6.07 (8.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 20.7
Fwd PE 68.5
P/S 5.19
P/FCF N/A
P/OCF N/A
P/B 5.43
P/tB N/A
EV/EBITDA 29.05
EPS(TTM)0.27
EY4.83%
EPS(NY)0.08
Fwd EY1.46%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.08
BVpS1.03
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 17.97%
ROE 26.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 14.87%
PM (TTM) 25.15%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.76
Altman-Z 8.15
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)350%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%533.33%
EPS Next Y-69.78%
EPS Next 2Y-9.18%
EPS Next 3Y8.49%
EPS Next 5Y41.76%
Revenue 1Y (TTM)22.99%
Revenue growth 3Y42.49%
Revenue growth 5Y28.65%
Sales Q2Q%10.42%
Revenue Next Year15.42%
Revenue Next 2Y18.38%
Revenue Next 3Y17.73%
Revenue Next 5Y17.75%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A